Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...

Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

Paul V. Goode, President and Chief Executive Officer, will give a corporate update on the Company’s Continuous Blood Glucose Monitor (CBGM). TechBio Showcase, as part of Biotech Showcase ...

These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result ...

"I am honored to join the Company at this pivotal time as we advance our human clinical trials and create a strategic regulatory program for the CBGM," Williams stated regarding his new role at ...

Paul V. Goode, President and Chief Executive Officer, will give a corporate update on the Company’s Continuous Blood Glucose Monitor (CBGM). TechBio Showcase, as part of Biotech ...

"Meeting these rigorous global standards for design and manufacturing demonstrates our dedication to quality and regulatory excellence as we continue to achieve clinical and developmental milestones ...